Aprea Therapeutics Q3 EPS $(0.86) Beats $(1.16) Estimate, Sales $319.47K Beat $80.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Aprea Therapeutics reported Q3 losses of $(0.86) per share, beating the analyst consensus estimate of $(1.16) by 25.86%. This is a 64.17% increase over losses from the same period last year. The company also reported quarterly sales of $319.47K, beating the analyst consensus estimate of $80.00K by 299.34%.
November 09, 2023 | 10:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aprea Therapeutics reported better than expected Q3 results, with losses per share and sales beating analyst estimates.
Aprea Therapeutics reported Q3 losses per share of $(0.86), which is better than the analyst consensus estimate of $(1.16). This is a significant improvement over the same period last year. Additionally, the company's sales of $319.47K also beat the analyst consensus estimate of $80.00K. This positive earnings report could lead to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100